Annie Mcguire Sells 2,283 Shares of Veracyte (NASDAQ:VCYT) Stock

Veracyte, Inc. (NASDAQ:VCYT) SVP Annie Mcguire sold 2,283 shares of the stock in a transaction that occurred on Friday, September 19th. The stock was sold at an average price of $33.69, for a total transaction of $76,914.27. Following the transaction, the senior vice president directly owned 91,599 shares in the company, valued at approximately $3,085,970.31. This represents a 2.43% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Veracyte Stock Down 4.3%

NASDAQ:VCYT opened at $32.68 on Thursday. The company has a market cap of $2.57 billion, a P/E ratio of 99.03 and a beta of 2.07. Veracyte, Inc. has a fifty-two week low of $22.61 and a fifty-two week high of $47.32. The firm’s 50 day moving average is $28.76 and its two-hundred day moving average is $28.99.

Hedge Funds Weigh In On Veracyte

A number of hedge funds have recently made changes to their positions in the business. Osaic Holdings Inc. raised its stake in shares of Veracyte by 289.9% in the 2nd quarter. Osaic Holdings Inc. now owns 1,201 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 893 shares during the period. FORA Capital LLC purchased a new stake in Veracyte during the 2nd quarter worth $206,000. Headlands Technologies LLC increased its stake in Veracyte by 74.8% during the 2nd quarter. Headlands Technologies LLC now owns 2,824 shares of the biotechnology company’s stock worth $76,000 after buying an additional 1,208 shares during the period. Tower Research Capital LLC TRC increased its stake in Veracyte by 401.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 19,201 shares of the biotechnology company’s stock worth $519,000 after buying an additional 15,371 shares during the period. Finally, Corient Private Wealth LLC increased its stake in Veracyte by 100.2% during the 2nd quarter. Corient Private Wealth LLC now owns 255,978 shares of the biotechnology company’s stock worth $6,915,000 after buying an additional 128,139 shares during the period.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. Wall Street Zen raised shares of Veracyte from a “hold” rating to a “buy” rating in a research note on Saturday, July 26th. Morgan Stanley set a $28.00 target price on shares of Veracyte and gave the company an “underweight” rating in a research note on Friday, August 8th. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Veracyte currently has an average rating of “Moderate Buy” and a consensus target price of $40.90.

Veracyte Company Profile

Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm’s portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.